Click Here for 5% Off Your First Aladdin Purchase!

J30-8 , CAS No.J611219, Inhibitor of mitogen-activated protein kinase 10

  • Moligand™
Item Number
J611219
Grouped product items
SKUSizeAvailabilityPrice Qty
J611219-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,334.90
J611219-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,001.90

Basic Description

Specifications & PurityMoligand™
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of mitogen-activated protein kinase 10

Associated Targets

YES1 Tclin Tyrosine-protein kinase Yes 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAPK10 Tchem Mitogen-activated protein kinase 10 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAPK8 Tchem Mitogen-activated protein kinase 8 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ABL1 Tclin Tyrosine-protein kinase ABL1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAPK9 Tchem Mitogen-activated protein kinase 9 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name 3-[(2Z,5Z)-2-[(2-chlorophenyl)imino]-4-oxo-1,3-thiazolidin-5-ylidene]-5-fluoro-2,3-dihydro-1H-indol-2-one
INCHI InChI=1S/C17H9ClFN3O2S/c18-10-3-1-2-4-12(10)21-17-22-16(24)14(25-17)13-9-7-8(19)5-6-11(9)20-15(13)23/h1-7H,(H,20,23)(H,21,22,24)/b14-13-
InChi Key HNOFQKYBQYGFNQ-YPKPFQOOSA-N
Canonical SMILES Fc1ccc2c(c1)/C(=C\1/S/C(=N\c3ccccc3Cl)/NC1=O)/C(=O)N2
Isomeric SMILES C1=CC=C(C(=C1)NC2=NC(=C(S2)C3=C4C=C(C=CC4=NC3=O)F)O)Cl
PubChem CID 4078145

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

References

1. Colombo A, Bastone A, Ploia C, Sclip A, Salmona M, Forloni G, Borsello T.  (2009)  JNK regulates APP cleavage and degradation in a model of Alzheimer's disease..  Neurobiol Dis,  33  (3): (518-25).  [PMID:19166938]
2. Triaca V, Sposato V, Bolasco G, Ciotti MT, Pelicci P, Bruni AC, Cupidi C, Maletta R, Feligioni M, Nisticò R et al..  (2016)  NGF controls APP cleavage by downregulating APP phosphorylation at Thr668: relevance for Alzheimer's disease..  Aging Cell,  15  (4): (661-72).  [PMID:27076121]
3. Dou X, Huang H, Li Y, Jiang L, Wang Y, Jin H, Jiao N, Zhang L, Zhang L, Liu Z.  (2019)  Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases..  J Med Chem,  62  (14): (6645-6664).  [PMID:31268308]

Solution Calculators